Joseph A. Vetro, PhD
Joseph A. Vetro, Ph.D.

Associate Professor

Department of Pharmaceutical Sciences
College of Pharmacy
University of Nebraska Medical Center
986025 Nebraska Medical Center
Omaha, NE 68198-6025
402-559-9359 (Office)
402-559-1975 (Lab)
402-559-5673 (Fax)

Teaching Activities:

Research Activities/Interests:

Dr. Vetro's research interests are in developing novel synthetic targeted drug and gene delivery nanocarriers for the anti-angiogenesis treatment of cancer, improving development paradigms for targeted bioimaging and drug delivery nanocarriers and developing subunit vaccines based on the novel adjuvant, EP67.

Recent Publications:

  1. Ambardekar VV, Wakaskar RR, Ye Z, Curran SM, McGuire TR, Coulter DW, Singh RK, Vetro JA (2018). Complexation of Chol-DsiRNA in place of Chol-siRNA greatly increases the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) in primary murine syngeneic breast tumors after i.v. administration. Int J Pharm. 543: 130-138.
  2. Karuturi VK, Tallapaka SB, Yeapuri P, Curran SM, Sanderson SD, Vetro JA. Encapsulation of an EP67-conjugated CTL peptide vaccine in nanoscale biodegradable particles increases the efficacy of respiratory immunization and affects the magnitude and memory subsets of vaccine-generated mucosal and systemic CD8+ T cells in a diameter-dependent manner (2017). Mol Pharm. DOI: 10.1021/acs.molpharmaceut.6b01088
  3. Bala Vamsi K. Karuturi, Shailendra B. Tallapaka, Joy A. Phillips, Sam D. Sanderson, Joseph A. Vetro (2015). Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant. Clinical Immunology 161: 251–259.
  4. Wakaskar RR, Bathena SPR, Tallapaka SB, Ambardekar VV, Gautam N, Thakare R, Simet SM, Curran SM, Dong Y, Vetro JA (2014). “Peripherally cross-linking the shell of core-shell polymer micelles decreases premature release of physically loaded combretastatin A4 in whole blood and increases its mean residence time and subsequent potency against primary murine breast tumors after IV administration.” Pharm Res. DOI: 10.1007/s11095-014-1515-z.
  5. Ambardekar VV, Wakaskar RR, Sharma B, Bowman J, Vayaboury W, Singh RK and Vetro JA (2013). "The efficacy of nuclease-resistant Chol-siRNA in primary breast tumors following complexation with PLL-PEG(5K)."Biomaterials 34(20): 4839-4848.
  6. Ambardekar VV, Han HY, Varney ML, Vinogradov SV, Singh RK and Vetro JA (2011). "The modification of siRNA with 3' cholesterol to increase nuclease protection and suppression of native mRNA by select siRNA polyplexes."Biomaterials 32(5): 1404-1411.
  7. Batrakova EV, Bronich TK, Vetro JA and Kabanov AV (2006). Polymeric micelles as drug carriers. Nanoparticulates as drug carriers. V. P. Torchilin. London, UK, Imperial College Press: 57-93.
  8. Braun CS, Vetro JA, Tomalia DA, Koe GS, Koe JG and Middaugh CR (2005). "Structure/function relationships of polyamidoamine/DNA dendrimers as gene delivery vehicles."J Pharm Sci 94(2): 423-436.
  9. Vetro JA, Dummitt B and Chang YH (2004). Methionine aminopeptidase: Emerging role in angiogenesis. Aminopeptidases in Biology and Disease. N. M. Hooper and U. Lendeckel. New York, New York, Kluwer: 17-44.
  10. Lobo BA, Vetro JA, Suich DM, Zuckermann RN and Middaugh CR (2003). "Structure/function analysis of peptoid/lipitoid:DNA complexes." J Pharm Sci 92(9): 1905-1918.